News | September 28, 2022
LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others
Funds raised will be used to develop technology and foster healthcare partnerships
Funds raised will be used to develop technology and foster healthcare partnerships
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
One in two women with advanced ovarian cancer has an HRD-positive tumor
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
The ANDA was filed as 'First to File' submission on NCE-1 date.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
